UKCA mark & UK MDR 2002 (devices)UKCA Medical Device Marking and UK Medical Devices Regulations Reform

UKCA stands for UK Conformity Assessed. MHRA's guidance describes it as a new route to market and product marking that became available after 1 January 2021 for manufacturers wishing to place medical devices on the Great Britain market — Great Britain meaning England, Wales and Scotland, not the whole of the UK. It sits alongside, rather than immediately replacing, the CE mark that manufacturers have used for decades under EU medical device law.

UKCA marking is built on the same underlying legal base as the CE route for GB purposes. MHRA's guidance explains that medical devices in Great Britain are regulated under the Medical Devices Regulations 2002 (SI 2002 No 618, as amended) (UK MDR 2002), which, before the end of the Brexit transition period, gave effect in UK law to three EU directives: the Active Implantable Medical Devices Directive 90/385/EEC, the Medical Devices Directive 93/42/EEC, and the In Vitro Diagnostic Medical Devices Directive 98/79/EC. Because the UK MDR 2002 is still derived from those directives rather than from the newer EU Medical Devices Regulation (EU MDR, 2017/745) or EU In Vitro Diagnostic Medical Devices Regulation (EU IVDR, 2017/746), the current GB route to market and UKCA marking requirements are themselves based on the older EU directive-era requirements.

A UKCA mark on its own does not put a device on the EU or Northern Ireland market — it is a GB-market-only marking. MHRA's guidance is explicit that the EU no longer recognises UK notified bodies, and that former UK notified bodies have become UK approved bodies that can issue UKCA certificates for GB but cannot issue CE certificates.

Separately from which mark a device carries, MHRA's guidance sets a registration requirement that applies regardless: all medical devices, including in vitro diagnostic medical devices (IVDs), custom-made devices, and systems or procedure packs, must be registered with the MHRA before they are placed on the Great Britain market. This registration obligation sits on top of, not instead of, the conformity marking requirement.

Where the device's manufacturer is based outside the UK, the MHRA will not accept a registration directly from that manufacturer — the manufacturer must appoint a single UK responsible person who registers and acts on the manufacturer's behalf for all of its devices, carrying out specified tasks that the guidance describes as including registration. The UK responsible person requirement is a recurring theme in UK post-Brexit product regulation generally, not something unique to medical devices, but MHRA's guidance sets out the device-specific detail of what that role covers.

The single most important practical fact for manufacturers is that the UK did not force a hard cut-over from CE to UKCA marking. Instead, the government has repeatedly extended the window in which CE-marked devices can still be placed on the GB market, specifically to avoid disrupting device supply while the UKCA system and UK approved body capacity built up. MHRA's guidance states plainly that the government has put in place legislation extending acceptance of CE-marked devices in Great Britain beyond the original 30 June 2023 deadline.

The gov.uk publication "Timelines for acceptance of CE marked medical devices in Great Britain (GB)" (published 16 February 2026) sets out the current legislative position, under the Medical Devices (Amendment) (Great Britain) Regulations 2023, which amend the UK MDR 2002. As stated on that page: general medical devices compliant with the EU Medical Devices Directive (EU MDD) or EU Active Implantable Medical Devices Directive (EU AIMDD), carrying a valid declaration and CE marking, can be placed on the GB market until the sooner of their certificate's expiry or 30 June 2028; in vitro diagnostic medical devices compliant with the EU In Vitro Diagnostic Medical Devices Directive (EU IVDD) can be placed on the GB market until the sooner of certificate expiry or 30 June 2030; and general medical devices (including custom-made devices) compliant with the newer EU Medical Devices Regulation (EU MDR), together with IVDs compliant with the EU In Vitro Diagnostic Medical Devices Regulation (EU IVDR), can be placed on the GB market until 30 June 2030.

A related gov.uk news release on the consultation notes that around 90% of medical devices currently used in Great Britain are CE marked, which is the practical reason the government is weighing indefinite recognition rather than pushing ahead with a full switch to UKCA-only supply.

Northern Ireland is treated separately under the Northern Ireland Regulations 2021, and MHRA's guidance is explicit that different rules apply there than in Great Britain. Since the EU Medical Devices Regulation (2017/745) and EU In Vitro Diagnostic Medical Devices Regulation (2017/746) took effect after the Brexit transition period ended — 26 May 2021 for EU MDR and 26 May 2022 for EU IVDR — they were not automatically retained as UK law under the EU (Withdrawal) Act 2018 and so do not apply in Great Britain. But they do continue to apply in Northern Ireland, alongside EU Member States, under the Northern Ireland Protocol/Windsor Framework arrangements.

The practical consequence is that a device destined for the Northern Ireland market generally needs to meet EU MDR or EU IVDR requirements and carry a CE mark issued under those regulations (or the relevant EU notified body route), not a UKCA mark, which has no standing in Northern Ireland. A manufacturer supplying both Great Britain and Northern Ireland therefore needs to think of them as two distinct regulatory markets with separate marking logic, even though both sit inside the United Kingdom. Readers working through the detail of how the Windsor Framework specifically affects medicines and devices moving into Northern Ireland should treat that as a related but separate topic from the GB transition timelines covered here.

Before Brexit, UK-based conformity assessment organisations operated as EU notified bodies, meaning they could assess devices against EU directive requirements and issue CE certificates recognised across the EU. MHRA's guidance states that this changed: the EU no longer recognises UK notified bodies, and UK notified bodies are not able to issue CE certificates — they have become UK approved bodies instead.

UK approved bodies now assess devices against UK MDR 2002 requirements and issue the certificates that support a UKCA mark for the GB market. The MHRA guidance also states that it is responsible for the designation and monitoring of UK conformity assessment bodies — in other words, MHRA plays the role for UK approved bodies that the EU Commission and member state competent authorities play for EU notified bodies. A manufacturer that previously held a CE certificate from a UK-based notified body before Brexit would, for continued EU or Northern Ireland market access, generally need a certificate from a body still recognised as an EU notified body — which by definition is no longer a UK-based body operating in that capacity for CE purposes.

For a device manufacturer or distributor operating in this space, the transition arrangements described above are not just a compliance-calendar entry — they shape day-to-day labelling, quality system, and production-record decisions that a company has to make now, while the underlying rules are still moving.

• Labelling: a device placed on the GB market under the CE transition arrangements can generally continue to carry its existing CE mark rather than needing to be relabelled with a UKCA mark, provided it still falls within the relevant timeline for its device category and directive/regulation basis. Getting the applicable deadline wrong — treating an EU MDR-compliant device as if it only had until 2028 rather than 2030, for example — risks either unnecessary relabelling cost or, worse, continuing to supply a device past its actual cut-off.
• Dual marking and market segregation: companies supplying both GB and EU/Northern Ireland markets often need processes that keep CE-only stock, UKCA-only stock, and dual-marked stock clearly distinguishable from goods-in through to despatch, since a device correctly marked for one market may not be lawful to supply into the other.
• Quality system scope: a manufacturer's quality management system documentation (whether aligned to ISO 13485 or another recognised framework) typically needs to record which conformity route — UK approved body / UKCA, or EU notified body / CE — applies to each product family, and which certificate and which regulator's requirements that route sits under, so that document control and management review can speak to the correct obligations for each market.
• Registration records: because MHRA registration is a separate, standing requirement from marking, batch and distribution records that support traceability should be able to show that the specific device batch or model was covered by a current MHRA registration (or by the UK responsible person's registration, where the manufacturer is based outside the UK) at the time it was placed on the GB market.
• Watching the live guidance, not a fixed date: because the February 2026 consultation on indefinite recognition is open and could change the 2028/2030 cut-offs described in this article, teams responsible for regulatory affairs should build a recurring check of the gov.uk guidance into their change-control or periodic-review process rather than hard-coding today's dates into permanent procedures.

It's worth being precise about what the transition arrangements do not do. They do not mean CE marking has become a permanent alternative to UKCA marking in Great Britain as a matter of settled law — the current legal position is a time-limited extension under specific legislation, even though the government is now consulting on making recognition of EU MDR/IVDR-compliant devices indefinite. They do not mean a UKCA mark gives any standing in the EU or Northern Ireland. And they do not remove the separate MHRA registration obligation, which applies regardless of which mark a device carries.

Manufacturers should also be careful not to conflate the UK MDR 2002 (the GB legal basis, still derived from the older EU directives) with the EU MDR 2017/745 (the newer EU regulation that applies in the EU and Northern Ireland but not in Great Britain) — the similar acronyms make this an easy mix-up, and the two frameworks differ in scope and detail, for example in how they treat software as a medical device, post-market surveillance, and classification rules.